Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
Hypertension, Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Hypertension focused on measuring nebivolol, Bystolic ™, Hypertension, Diabetes
Eligibility Criteria
INCLUSION CRITERIA:
- Male or female, 18-85 years of age
- Blood pressure in the range of 130 to 179/80 to 109 mmHg
- Currently using either an ACE inhibitor or an ARB alone or (an ACE inhibitor or an ARB and up to two other drugs for treatment of high blood pressure). (Patients may be on both an ACE inhibitor and ARB, but would need to be taken off one.)
- Stable medication regimen for high blood pressure for at least one month prior to screening
- Stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin
- HgbA1c 6.5 to 8.5% (This is measured at the screening visit)
EXCLUSION CRITERIA:
- Use of any beta blocker within one month prior to screening
- Use of clonidine within 3 months prior to screening
- Diagnosis of hyperthyroidism as evidenced by abnormal lab markers
- Any disorder requiring the intermittent or chronic use of systemic corticosteroids
- Diagnosis of hyperthyroidism as determined by lab markers done at screening
- Active liver disease as determined by lab markers
- Kidney impairment; estimated GFR < 60 mL/min/1.73 m2
- History of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or TIA in 3 months prior to screening
- Chronic heart failure
- Drug or alcohol abuse within 2 years prior to screening
- History of sensitivity to any beta blocker, HCTZ, sulfa drug, or calcium channel blocker
- Participation in another research study within 30 days prior to screening
Sites / Locations
- Forest Investigative Site 15
- Forest Investigative Site 16
- Forest Investigative Site 35
- Forest Investigative Site
- Forest Investigative Site 54
- Forest Investigative Site 40
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site 55
- Forest Investigative Site 11
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site 49
- Forest Investigative Site 47
- Forest Investigative Site 61
- Forest Investigative Site
- Forest Investigative Site 3
- Forest Investigative Site 33
- Forest Investigative Site 36
- Forest Investigative Site 62
- Forest Investigative Site 080
- Forest Investigative Site 59
- Forest Investigative Site 32
- Forest Investigative Site 081
- Forest Investigative Site 2
- Forest Investigative Site
- Forest Investigative Site 19
- Forest Investigative Site 44
- Forest Investigative Site 5
- Forest Investigative Site 56
- Forest Investigative Site 57
- Forest Investigative Site 39
- Forest Investigative Site 37
- Forest Investigative Site
- Forest Investigative Site 20
- Forest Investigative Site 50
- Forest Investigative Site 21
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site 7
- Forest Investigative Site 45
- Forest Investigative Site 24
- Forest Investigative Site 26
- Forest Investigative Site 18
- Forest Investigative Site 51
- Forest Investigative Site 48
- Forest Investigative Site 12
- Forest Investigative Site 17
- Forest Investigative Site 46
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site 4
- Forest Investigative Site 10
- Forest Investigative Site 52
- Forest Investigative Site 28
- Forest Investigative Site 38
- Forest Investigative Site 34
- Forest Investigative Site
- Forest Investigative Site
- Forest Investigative Site 31
- Forest Investigative Site 41
- Forest Investigative Site 60
- Forest Investigative Site 29
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
1
2
3
Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration Open-label amlodipine may be given
Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration Open-label amlodipine may be given
HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration Open-label amlodipine may be given